Phase III Clinical Development of Toremifene on Course

GTx, Inc. announced that following a planned safety review, an independent Data Safety Monitoring Board has recommended that the company continue as planned the pivotal Phase III clinical trial evaluating toremifene 20 mg for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia, a precancerous lesion of the prostate.
iStockAnalyst